Scarica l'app Stockscreener
3.814
3.38%
0.114
Precedente Chiudi:
$3.70
Aprire:
$3.71
Volume 24 ore:
967.07K
Relative Volume:
0.76
Capitalizzazione di mercato:
$326.96M
Reddito:
-
Utile/perdita netta:
$-36.95M
Rapporto P/E:
-4.5405
EPS:
-0.84
Flusso di cassa netto:
$-33.46M
1 W Prestazione:
+1.46%
1M Prestazione:
+13.17%
6M Prestazione:
+16.97%
1 anno Prestazione:
-49.47%
Intervallo 1D:
$3.61
$3.95
Intervallo di 1 settimana:
$3.415
$3.9733
Portata 52W:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Confronta LRMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.82 | 323.53M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.35 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.73 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.42 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.25 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
What are Larimar Therapeutics Inc.’s recent SEC filings showingBest Small Caps with Big Returns - classian.co.kr
RSI Crosses Above 30 for Larimar Therapeutics Inc. — Reversal in SightEarly Entry Tips With Low Risk Zone Shared - 선데이타임즈
Will Larimar Therapeutics Inc. stock recover after earnings300% Return Stock Forecast - thegnnews.com
Will Larimar Therapeutics Inc. benefit from rising consumer demandTop Earnings Growth Momentum Picks - newsyoung.net
Larimar Therapeutics: Institutional Confidence and Capital-Raising Strategy Signal Conviction in Long-Term Pipeline - AInvest
Institutional Investors Hold 40% Stake in Larimar Therapeutics - AInvest
With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance
Larimar Therapeutics Insider Bought Shares Worth $30,000,000, According to a Recent SEC Filing - 富途牛牛
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
Larimar Therapeutics Sees Significant Stock Purchase by Director - AInvest
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement - Quiver Quantitative
Mintz Advises on Larimar Therapeutics’ $69 Million Public Offering - Mintz
Massive Stock Purchase by Larimar Therapeutics Director! - TipRanks
Larimar therapeutics: Deerfield funds buy $10.8m in shares By Investing.com - Investing.com Canada
Larimar therapeutics: Deerfield funds buy $10.8m in shares - Investing.com India
Larimar Therapeutics stock price target lowered to $10 at Jones Trading - Investing.com Canada
Why is Larimar Therapeutics Inc. stock attracting strong analyst attentionCapitalize on high-growth stocks early - Jammu Links News
What analysts say about Larimar Therapeutics Inc. stockCapitalize on high-yield stocks early - Jammu Links News
What institutional investors are buying Larimar Therapeutics Inc. stockAchieve exceptional returns with expert guidance - Jammu Links News
What catalysts could drive Larimar Therapeutics Inc. stock higher in 2025Build wealth steadily with expert advice - Jammu Links News
How does Larimar Therapeutics Inc. compare to its industry peersBuild a portfolio that withstands market volatility - Jammu Links News
What are analysts’ price targets for Larimar Therapeutics Inc. in the next 12 monthsUnmatched profit potential - Jammu Links News
Should I hold or sell Larimar Therapeutics Inc. stock in 2025Discover stocks with strong growth potential - Jammu Links News
Is Larimar Therapeutics Inc. a good long term investmentCapitalize on market shifts before others do - Jammu Links News
What are the technical indicators suggesting about Larimar Therapeutics Inc.Unlock powerful market insights for success - Jammu Links News
What are Larimar Therapeutics Inc. company’s key revenue driversDiscover breakthrough stocks before the crowd - Jammu Links News
Larimar Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Larimar Therapeutics raises $69 million in public offering - Investing.com
Larimar Therapeutics raises $69 million in public offering By Investing.com - Investing.com Nigeria
Larimar Therapeutics Announces $64.4 Million Stock Offering - The Globe and Mail
Why Larimar Therapeutics Inc. is moving todayAutomated AI Forecast with Trading Alerts - Newser
Relative strength of Larimar Therapeutics Inc. in sector analysisSmart Trade Mapping with Entry Details - Newser
Analyzing recovery setups for Larimar Therapeutics Inc. investorsOversold Reversal Picks with Buy Zone - Newser
Larimar Therapeutics Raises $64.4 Million in Stock Offering - AInvest
Short interest data insights for Larimar Therapeutics Inc.Free Real-Time Market Sentiment Tracking Tool - Newser
Larimar Therapeutics Announces Closing of Underwritten - GlobeNewswire
Larimar Therapeutics Announces Closing of Underwritten Public Of - GuruFocus
Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates - Quiver Quantitative
Larimar Therapeutics Raises $69M in Oversubscribed Public Offering - AInvest
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
Rare Disease Biotech Larimar Secures $69M Windfall as Investors Rush to Oversubscribed Stock Offering - Stock Titan
Using R and stats models for Larimar Therapeutics Inc. forecastingShort-Term AI-Based Stock Price Forecast - Newser
What recovery options are there for Larimar Therapeutics Inc.Free High Win Rate Trading Opportunities - Newser
What indicators show strength in Larimar Therapeutics Inc.Predictive System for Long-Term Stock Forecast - Newser
Is it time to cut losses on Larimar Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
Is Larimar Therapeutics Inc. stock overhyped or has real potentialFree Trade Setups With AI Powered Filters - Newser
Will Larimar Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Larimar Therapeutics Announces Public Offering, Drops 20% in Share Price - AInvest
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):